Roche Escapes EMA Rebuke on Drug Safety

Washington Drug Letter
A A
The European Medicines Agency (EMA) has concluded a review of adverse event reporting deficiencies at Roche, concluding the company’s failure last year to report adverse events for 19 drugs did not cause any additional risks to consumers.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $25.00